Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.31 USD
+0.02 (7.94%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Cara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 21 | 42 | 23 | 135 | 20 |
Cost Of Goods | 6 | 7 | 0 | 0 | 0 |
Gross Profit | 15 | 35 | 23 | 135 | 20 |
Selling & Adminstrative & Depr. & Amort Expenses | 136 | 122 | 112 | 130 | 132 |
Income After Depreciation & Amortization | -122 | -88 | -89 | 5 | -112 |
Non-Operating Income | 3 | 2 | 1 | 2 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -119 | -85 | -88 | 8 | -107 |
Income Taxes | 0 | 0 | 0 | -1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -119 | -85 | -88 | 8 | -106 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -119 | -85 | -88 | 8 | -106 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -120 | -86 | -87 | 7 | -112 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 2 | 1 | -1 |
Income After Depreciation & Amortization | -122 | -88 | -89 | 5 | -112 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 54.15 | 53.65 | 50.72 | 47.92 | 42.67 |
Diluted EPS Before Non-Recurring Items | -2.19 | -1.59 | -1.74 | 0.18 | -2.49 |
Diluted Net EPS (GAAP) | -2.19 | -1.59 | -1.74 | 0.18 | -2.49 |
Fiscal Year end for Cara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.99 | 2.14 | 3.00 | 4.87 | 6.93 |
Cost Of Goods | 0.00 | 0.62 | 0.61 | 1.56 | 1.42 |
Gross Profit | 0.99 | 1.52 | 2.40 | 3.31 | 5.52 |
SG&A, R&D, and Dept/Amort Expenses | 18.30 | 31.18 | 35.01 | 32.21 | 37.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.31 | -29.66 | -32.61 | -28.90 | -32.34 |
Non-Operating Income | -2.71 | -1.03 | 0.27 | 0.87 | 0.86 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -20.02 | -30.70 | -32.34 | -28.03 | -31.48 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -20.02 | -30.70 | -32.34 | -28.03 | -31.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -20.02 | -30.70 | -32.34 | -28.03 | -31.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 54.73 | 54.59 | 54.48 | 54.24 | 54.00 |
Diluted EPS Before Non-Recurring Items | -0.37 | -0.56 | -0.59 | -0.52 | -0.58 |
Diluted Net EPS (GAAP) | -0.37 | -0.56 | -0.60 | -0.52 | -0.58 |